DE60331725D1 - Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren - Google Patents

Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren

Info

Publication number
DE60331725D1
DE60331725D1 DE60331725T DE60331725T DE60331725D1 DE 60331725 D1 DE60331725 D1 DE 60331725D1 DE 60331725 T DE60331725 T DE 60331725T DE 60331725 T DE60331725 T DE 60331725T DE 60331725 D1 DE60331725 D1 DE 60331725D1
Authority
DE
Germany
Prior art keywords
therapeutic
anticroble
adjuvanties
vaccine
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331725T
Other languages
English (en)
Inventor
Eric Simard
Philippe Goyette
Pierre Lemieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TECHNOLOGIE BIOLACTIS Inc
Original Assignee
TECHNOLOGIE BIOLACTIS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TECHNOLOGIE BIOLACTIS Inc filed Critical TECHNOLOGIE BIOLACTIS Inc
Application granted granted Critical
Publication of DE60331725D1 publication Critical patent/DE60331725D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60331725T 2002-03-25 2003-03-25 Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren Expired - Lifetime DE60331725D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36653102P 2002-03-25 2002-03-25
PCT/CA2003/000434 WO2003080111A2 (en) 2002-03-25 2003-03-25 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
DE60331725D1 true DE60331725D1 (de) 2010-04-29

Family

ID=28454811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331725T Expired - Lifetime DE60331725D1 (de) 2002-03-25 2003-03-25 Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren

Country Status (7)

Country Link
US (2) US20060051354A1 (de)
EP (1) EP1490098B1 (de)
AT (1) ATE460943T1 (de)
AU (1) AU2003212170A1 (de)
CA (1) CA2479528A1 (de)
DE (1) DE60331725D1 (de)
WO (1) WO2003080111A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
CN103463630A (zh) * 2005-11-02 2013-12-25 杜克大学 同时的化学疗法和免疫疗法
US20090285834A1 (en) * 2005-11-24 2009-11-19 Dainippon Sumitomo Pharma Co., Ltd. Novel memory ctl induction potentiator
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CN101766815B (zh) * 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2012054425A2 (en) * 2010-10-18 2012-04-26 University Of Iowa Research Foundation Biodegradable particulate formulations
WO2014153636A1 (en) * 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
WO2021051066A1 (en) * 2019-09-13 2021-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Her3 pulsed dc1 therapy
CN111518169B (zh) * 2020-04-29 2021-07-06 潍坊医学院 一种多肽、多肽纳米载药载体及两者的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CA2267977A1 (en) * 1996-10-16 1998-04-23 Matthew G. Ewend Cytokine enhanced immunotherapy for brain tumors

Also Published As

Publication number Publication date
CA2479528A1 (en) 2003-10-02
AU2003212170A8 (en) 2003-10-08
WO2003080111A2 (en) 2003-10-02
WO2003080111A3 (en) 2003-11-13
EP1490098A2 (de) 2004-12-29
US20060051354A1 (en) 2006-03-09
US20100272676A1 (en) 2010-10-28
AU2003212170A1 (en) 2003-10-08
EP1490098B1 (de) 2010-03-17
ATE460943T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
TW200602077A (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
EA200702633A1 (ru) Вакцина против малярии
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
ATE499112T1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
DE60043708D1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
GB0109297D0 (en) Vaccine
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
WO2002053176A3 (en) An autologous anti-cancer vaccine
EA200700017A1 (ru) Способ усиления иммунного ответа на вакцину
ATE447968T1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
WO2002100317A3 (en) Targeted particles and methods of using the same
AR034621A1 (es) Formulaciones
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
WO2004017919A3 (en) Use of mullerian inhibiting substance and interferon for treating tumors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition